Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 28, 2013; 19(40): 6834-6841
Published online Oct 28, 2013. doi: 10.3748/wjg.v19.i40.6834
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Study patient flow. HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Cumulative risk. A, B: Hepatocellular carcinoma (HCC) in cirrhotic patients and in HBeAg (+) patients with drug-resistant chronic hepatitis B (CHB) (log rank test, P < 0.001, P = 0.008, respectively); C, D: HCC in YIDD patients and in patients > 50 years of age with drug-resistant CHB (log rank test, P =0.007, P = 0.001, respectively); E: HCC in complete virologic responders with drug-resistant CHB (log rank test, P = 0.003).